Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
1 IntroductionIn recent times, focused remedy has achieved vital success in superior non-small cell lung most cancers (NSCLC). Sufferers with metastatic lung most...
IND for medical research for mixture remedy with hormone remedy in prostate most cancers sufferers to be submitted in August, 2024.
Niclosamide-based metabolic anticancer...
